Bicycle Therapeutics raising $230m growth capital

Business Weekly reported in March that the company would be looking to generate more growth funding despite having $339.2 million cash – a runway to take the Nasdaq-quoted company into 2025.

The company has grown headcount and facilities in the UK and in the Boston cluster in the US and its drug pipeline is accelerating fast.